Extended Data Fig. 3: Evaluation of Tcm- and Tn/mem-derived CAR-T cell products for Treg cells. | Nature Medicine

Extended Data Fig. 3: Evaluation of Tcm- and Tn/mem-derived CAR-T cell products for Treg cells.

From: Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

Extended Data Fig. 3: Evaluation of Tcm- and Tn/mem-derived CAR-T cell products for Treg cells.

a, UMAP projection and log-normalized, scaled expression of CTLA4 (with 12 clusters indicated as in Fig. 2b), IL2RA, FOXP3 and IKZF2 genes. b, Average expression, and the percentages of cells expressing CTLA4, IL2RA, FOXP3 or IKZF2 genes in each of the 12 clusters identified by scRNA sequencing (C0-C11). c, Representative flow cytometry of CD25/FOXP3 on viable, CD3+/CD4+/CAR(CD19t)+ -gated cells of either Tcm- or Tn/mem-derived CAR-T cell products as compared to a Treg CAR-T cell line control. Isotype control staining is depicted at top to confirm quadrant placement for each analysis. d, Mean (±S.E.) percentages of CD25/FOXP3+ cells (left) or mean fluorescence intensities (MFI) of FOXP3 expression (right) on viable, CD3+/CD4+/CAR(CD19t)+ -gated cells of n = 5 representative Tcm- or Tn/mem-derived CAR-T cell products as compared to a Treg CAR-T cell line control.

Back to article page